ABUS
Arbutus Biopharma Corporation NASDAQ$4.39
Mkt Cap $864.6M
52w Low $2.94
67.1% of range
52w High $5.10
50d MA $4.44
200d MA $4.25
P/E (TTM)
-25.4x
EV/EBITDA
-34.0x
P/B
10.8x
Debt/Equity
0.1x
ROE
-43.8%
P/FCF
-23.3x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$4.44
200d MA
$4.25
Avg Volume
2.4M
About
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replica…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.04 | -0.01 | +71.3% | 4.42 | -2.3% | -2.5% | +2.5% | +0.7% | -2.9% | -2.7% | +0.2% | — |
| Nov 13, 2025 | AMC | -0.06 | -0.04 | +28.6% | 4.56 | -1.3% | -0.9% | -0.4% | -2.4% | -6.4% | -7.9% | +8.6% | — |
| Aug 6, 2025 | AMC | -0.02 | 0.01 | +150.0% | 3.47 | +1.7% | -2.0% | -2.0% | -3.5% | -2.0% | -2.9% | +21.0% | — |
| May 14, 2025 | AMC | -0.09 | -0.13 | -44.4% | 3.16 | -0.9% | -1.3% | -2.5% | -0.9% | +1.6% | +0.3% | +11.7% | — |
| Mar 27, 2025 | AMC | -0.08 | -0.07 | +12.5% | 3.27 | +0.0% | +7.0% | +6.7% | +6.4% | +7.3% | +7.3% | +2.1% | — |
| Nov 6, 2024 | AMC | -0.10 | -0.10 | +0.0% | 3.92 | +0.0% | -4.8% | -4.3% | -4.8% | -7.1% | -6.9% | -6.1% | — |
| Aug 1, 2024 | AMC | -0.10 | -0.11 | -10.0% | 3.81 | -3.1% | -1.8% | -5.0% | -5.0% | -7.9% | -5.5% | +4.7% | — |
| May 2, 2024 | AMC | -0.10 | -0.10 | +0.0% | 2.68 | +1.1% | +1.1% | +4.5% | +6.0% | +6.0% | +9.7% | +27.6% | — |
| Feb 29, 2024 | AMC | -0.12 | -0.12 | +0.0% | 2.80 | -0.7% | -0.4% | -3.2% | -4.6% | -2.1% | -3.6% | -8.6% | — |
| Nov 7, 2023 | AMC | -0.12 | -0.12 | +0.0% | 1.85 | +1.1% | +1.1% | -2.7% | -4.3% | -3.2% | +1.6% | +12.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $4.56 | $4.50 | -1.3% | -0.9% | -0.4% | -2.4% | -6.4% | -7.9% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $3.40 | $3.40 | +0.0% | -1.5% | +0.0% | -0.9% | -0.9% | -0.9% |
| Mar 28 | Chardan Capital | Maintains | Buy → Buy | — | $3.27 | $3.27 | +0.0% | +7.0% | +6.7% | +6.4% | +7.3% | +7.3% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.20 | $3.19 | -0.3% | +0.3% | +0.6% | +4.4% | +3.8% | +7.2% |
| Nov 20 | Chardan Capital | Maintains | Buy → Buy | — | $3.49 | $3.53 | +1.1% | -1.4% | -0.9% | +0.6% | -2.0% | -2.3% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.64 | $3.64 | +0.0% | -3.3% | -4.1% | -5.5% | -4.9% | -3.6% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $3.92 | +0.0% | -4.8% | -4.3% | -4.8% | -7.1% | -6.9% |
| Nov 6 | Chardan Capital | Maintains | Buy → Buy | — | $3.96 | $3.85 | -2.8% | -1.0% | -5.8% | -5.3% | -5.8% | -8.1% |
| Sep 5 | Jefferies | Maintains | Buy → Buy | — | $4.09 | $4.18 | +2.2% | +10.3% | +11.2% | +9.8% | +11.5% | +11.5% |
| Aug 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.81 | $3.69 | -3.1% | -1.8% | -5.0% | -5.0% | -7.9% | -5.5% |
Recent Filings
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
FDA Fast Track designation for imdusiran accelerates hepatitis B development timeline and potential market entry, improving commercialization prospects and de-risking the program for shareholders.
Apr 15
8-K
Unknown — 8-K Filing
Arbutus maintained disciplined spending and extended cash runway in Q4 2025, signaling management confidence in funding operations through key clinical milestones without dilutive financing.
Mar 23
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Settlement with Moderna likely ends costly litigation risk for these biotech companies, potentially freeing resources for R&D and improving profit visibility going forward.
Mar 23
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and Genevant entered a settlement agreement on March 3, 2026, resolving an unspecified dispute between the companies.
Mar 3
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and licensee Genevant won a Delaware court ruling in their patent infringement litigation against Moderna, potentially securing damages for technology violations.
Feb 20
8-K · 8.01
!! High
Arbutus Biopharma Corporation -- 8-K 8.01: Material Event / Announcement
Arbutus Biopharma and its licensee Genevant won a Delaware court ruling against Moderna regarding patent infringement damages, potentially securing financial compensation for unauthorized use of their intellectual property.
Feb 6
Data updated apr 24, 2026 10:20am
· Source: massive.com